Phenprocoumon

Known as: Phenylpropylhydroxycumarinum, 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one, 3-(alpha-Phenylpropyl)-4-hydroxycoumarin

An orally available, long-acting derivative of coumarin with anticoagulant activity. Upon administration, phenprocoumon inhibits the vitamin K…

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2012

Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients -

Highly Cited

2009

Highly Cited

2009

The course of long-term anticoagulant therapy in 114 out-patients has been evaluated over a three-month period. The evaluation…

2009

Abstract Two comparable groups, each of which comprised 41 patients, were treated with long-acting phenprocoumon and short-acting…

2009

The purpose of this study was to assess the predictive values of the assays of fibrinopeptide A (FPA), beta-thromboglobulin (BTG…

2004

SummaryPhenprocoumon was given orally to 9 patients with biopsy proven liver cirrhosis (dose range 0.12–0.25 mg/kg) and to 7…

1999

A 9-year series of 45 intracranial and spinal hematomas in patients under oral anticoagulant treatment with phenprocoumon was…

1983

SummaryThis study was based on the clinical observation of a higher phenprocoumon requirement in these diabetic patients…

1976

Phenprocoumon is extracted from acidified plasma, the organic phase evaporated, and part of the residue, in ethanol, is…

1975

The metabolic fate of phenprocoumon [3-(alpha-ethylbenzyl)-4-hydroxycoumarin] in the rat is described. The major metabolites, 4…

1972

SummaryThe effect of cholestyramine on the absorption of phenprocoumon and acetylosalicylic acid has been studied in volunteers…